07.09.14
Aesica Pharmaceuticals has added services to its oral solids capability with a new roller compaction unit for dry granulation production in Zwickau, Germany. The roller compaction unit uses a continuous production step designed to enhance product uniformity for pharmaceutical formulation technologies that enable the formulation of APIs otherwise inhibited by the presence of water.
This represents the company’s latest investment in the region, including a new tablet coater capability and pouch packing line.
Ian Muir, managing director, Finished Dose at Aesica, said, “This new investment aligns with our strategy of investing in our German sites to broaden capabilities, which is expanding our domestic market share within Germany, whilst allowing us to offer new services to our global customers. The dry granulation capability will drive business growth as customers with moisture sensitive APIs seek appropriate technologies, and crucially, experienced CDMOs that can deliver their products.”
This represents the company’s latest investment in the region, including a new tablet coater capability and pouch packing line.
Ian Muir, managing director, Finished Dose at Aesica, said, “This new investment aligns with our strategy of investing in our German sites to broaden capabilities, which is expanding our domestic market share within Germany, whilst allowing us to offer new services to our global customers. The dry granulation capability will drive business growth as customers with moisture sensitive APIs seek appropriate technologies, and crucially, experienced CDMOs that can deliver their products.”